Kim Nalee, Lee Joongyo, Shin Hyunju, Shin Jungwook, Nam Do-Hyun, Lee Jung-Il, Seol Ho Jun, Kong Doo-Sik, Choi Jung Won, Chong Kyuha, Lee Won Jae, Chang Jong Hee, Kang Seok-Gu, Moon Ju Hyung, Cho Jaeho, Lim Do Hoon, Yoon Hong In
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea.
Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clin Transl Radiat Oncol. 2024 May 22;47:100799. doi: 10.1016/j.ctro.2024.100799. eCollection 2024 Jul.
Severe lymphopenia (SLP) has emerged as a significant prognostic factor in glioblastoma. Intensity-modulated radiation therapy (IMRT)-based radiation therapy (RT) is suggested to minimize the risk of SLP. This study aimed to evaluate SLP incidence based on multi-institutional database in patients with GBM treated with IMRT and develop a predictive nomogram.
This retrospective study reviewed data from 348 patients treated with IMRT-based concurrent chemoradiation therapy (CCRT) at two major hospitals from 2016 to 2021. After multivariate regression analysis, a nomogram was developed and internally validated to predict SLP risk.
During treatment course, 21.0% of patients developed SLP and SLP was associated with poor overall survival outcomes in patients with GBM. A newly developed nomogram, incorporating gender, pre-CCRT absolute lymphocyte count, and brain mean dose, demonstrated fair predictive accuracy (AUC 0.723).
This study provides the first nomogram for predicting SLP in patients with GBM treated with IMRT-based CCRT, with acceptable predictive accuracy. The findings underscore the need for dose optimization and radiation planning to minimize SLP risk. Further external validation is crucial for adopting this nomogram in clinical practice.
严重淋巴细胞减少(SLP)已成为胶质母细胞瘤的一个重要预后因素。基于调强放射治疗(IMRT)的放射治疗(RT)被认为可将SLP风险降至最低。本研究旨在基于多机构数据库评估接受IMRT治疗的胶质母细胞瘤患者的SLP发生率,并制定一个预测列线图。
这项回顾性研究回顾了2016年至2021年在两家主要医院接受基于IMRT的同步放化疗(CCRT)的348例患者的数据。经过多变量回归分析,制定了一个列线图并进行内部验证以预测SLP风险。
在治疗过程中,21.0%的患者出现SLP,且SLP与胶质母细胞瘤患者较差的总生存结果相关。一个新开发的列线图,纳入了性别、CCRT前绝对淋巴细胞计数和脑平均剂量,显示出较好的预测准确性(AUC 0.723)。
本研究为接受基于IMRT的CCRT治疗的胶质母细胞瘤患者提供了首个预测SLP的列线图,具有可接受的预测准确性。研究结果强调了进行剂量优化和放射治疗计划以将SLP风险降至最低的必要性。进一步的外部验证对于在临床实践中采用该列线图至关重要。